EDGAR·FLOW

Aclaris Therapeutics, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 72/100
What the filing says
Aclaris announced on November 16, 2026 that its Phase 2 ADMIRATION trial of bosakitug (ATI-045), an anti-TSLP monoclonal antibody for atopic dermatitis, did not achieve primary or secondary endpoints, though pharmacodynamic data showed robust target engagement. The company is refocusing development on modzatinib (ITK/JAK3 inhibitor, Phase 2b in lichen planus initiated), ATI-9494 (ITK inhibitor, IND filing expected Q4 2026), and ATI-052 (anti-TSLP/IL-4R bispecific, Phase 2b in eosinophilic esophagitis planned Q1 2027). No specific dollar impact or financial terms disclosed.
Why this rating

Major Phase 2 failure removes pipeline asset but company retains three active programs with regulatory pathway forward. At $149M market cap, clinical-stage loss is material, but strategic pivot mitigates trajectory risk.

Tradability signal
NO TRADE

No trade: negative news, but this cell's evidence is too weak. Similar past filings (342 in this cell) moved -1.08% in the called direction over 4 hrs; shrunk for sample size that's a -1.00% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
before filing · preread
$3.35 ▼ 3.87%
at our read · unknown
$3.48
+10 min · unknown
$3.50 ▲ 0.57%
+30 min · unknown
$3.51 ▲ 0.72%
+1 hr · unknown
$3.48 ▲ 0.00%
+4 hrs · unknown
$3.54 ▲ 1.58%

The stock had already moved +4.03% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ACRS · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.